|Awarded On||February 15, 2023|
|Title||School-based Human Papillomavirus Vaccination Program in the Rio Grande Valley: Continuation and Expansion in Hidalgo, Cameron, and Willacy Counties|
|Award Mechanism||Primary Prevention of Cancer|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Ana Rodriguez|
*Pending contract negotiation
Need: The human papillomavirus (HPV) vaccine serves as an effective primary prevention strategy  to reduce morbidity and mortality of HPV-associated diseases (cervical, oropharyngeal, vulvar, vaginal, penile, and anal cancers, and anogenital warts). However, there are an estimated 46,143 new cases of HPV-associated cancers diagnosed in the U.S. in each year  and estimated 4,280 HPV-associated cancer deaths from these cases. Moreover, the lifetime medical costs of diseases attributable to HPV infections acquired in 2018 surpass $770 million . Morbidity, mortality, and direct costs could decrease if vaccination increased . However, in 2020, only 61.4% of adolescent girls and 56.0% ...